Literature DB >> 16432528

Treatment-resistant bipolar disorder.

M Gitlin1.   

Abstract

Despite the remarkable increase in medications validated as effective in bipolar disorder, treatment is still plagued by inadequate response in acute manic or depressive episodes or in long-term preventive maintenance treatment. Established first-line treatments include lithium, valproate and second-generation antipsychotics (SGAs) in acute mania, and lithium and valproate as maintenance treatments. Recently validated treatments include extended release carbamazapine for acute mania and lamotrigine, olanzapine and aripiprazole as maintenance treatments. For treatment-resistant mania and as maintenance treatments, a number of newer anticonvulsants, and one older one, phenytoin, have shown some promise as effective. However, not all anticonvulsants are effective and each agent needs to be evaluated individually. Combining multiple agents is the most commonly used clinical strategy for treatment resistant bipolar patients despite a relative lack of data supporting its use, except for acute mania (for which lithium or valproate plus an SGA is optimal treatment). Other approaches that may be effective for treatment-resistant patients include high-dose thyroid augmentation, clozapine, calcium channel blockers and electroconvulsive therapy (ECT). Adjunctive psychotherapies show convincing efficacy using a variety of different techniques, most of which include substantial attention to education and enhancing coping strategies. Only recently, bipolar depression has become a topic of serious inquiry with the dominant controversy focusing on the place of antidepressants in the treatment of bipolar depression. Other than mood stabilizers alone or the combination of mood stabilizers and antidepressants, most of the approaches for treatment-resistant bipolar depression are relatively similar to those used in unipolar depression, with the possible exception of a more prominent place for SGAs, prescribed either alone or in combination with antidepressants. Future work in the area needs to explore the treatments commonly used by clinicians with inadequate research support, such as combination therapy and the use of antidepressants as both acute and adjunctive maintenance treatments for bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432528     DOI: 10.1038/sj.mp.4001793

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  34 in total

1.  Amphetamine-induced appetitive 50-kHz calls in rats: a marker of affect in mania?

Authors:  Marcela Pereira; Roberto Andreatini; Rainer K W Schwarting; Juan C Brenes
Journal:  Psychopharmacology (Berl)       Date:  2014-01-11       Impact factor: 4.530

Review 2.  Tamoxifen use for the management of mania: a review of current preclinical evidence.

Authors:  Fernanda Armani; Monica Levy Andersen; José Carlos Fernandes Galduróz
Journal:  Psychopharmacology (Berl)       Date:  2014-01-18       Impact factor: 4.530

Review 3.  Glutamatergic modulators: the future of treating mood disorders?

Authors:  Carlos Zarate; Rodrigo Machado-Vieira; Ioline Henter; Lobna Ibrahim; Nancy Diazgranados; Giacomo Salvadore
Journal:  Harv Rev Psychiatry       Date:  2010 Sep-Oct       Impact factor: 3.732

Review 4.  Bipolar disorder: candidate drug targets.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Mt Sinai J Med       Date:  2008 May-Jun

5.  A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania.

Authors:  Rodrigo Machado-Vieira; Jair C Soares; Diogo R Lara; David A Luckenbaugh; João V Busnello; Getulio Marca; Angelo Cunha; Diogo O Souza; Carlos A Zarate; Flavio Kapczinski
Journal:  J Clin Psychiatry       Date:  2008-08       Impact factor: 4.384

6.  Can cycles of chills and fever resolve bipolar disorder mania?

Authors:  Audun Setsaas; Arne Einar Vaaler
Journal:  BMJ Case Rep       Date:  2014-04-11

7.  Affective instability and the course of bipolar depression: results from the STEP-BD randomised controlled trial of psychosocial treatment.

Authors:  Jonathan P Stange; Louisa G Sylvia; Pedro Vieira da Silva Magalhães; David J Miklowitz; Michael W Otto; Ellen Frank; Christine Yim; Michael Berk; Darin D Dougherty; Andrew A Nierenberg; Thilo Deckersbach
Journal:  Br J Psychiatry       Date:  2016-01-21       Impact factor: 9.319

8.  Extreme attributions predict the course of bipolar depression: results from the STEP-BD randomized controlled trial of psychosocial treatment.

Authors:  Jonathan P Stange; Louisa G Sylvia; Pedro Vieira da Silva Magalhães; David J Miklowitz; Michael W Otto; Ellen Frank; Michael Berk; Andrew A Nierenberg; Thilo Deckersbach
Journal:  J Clin Psychiatry       Date:  2013-03       Impact factor: 4.384

9.  Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.

Authors:  Hideki Taoka; Takashi Hamamura; Shiro Endo; Shinji Miyata; Kishio Toma; Takeshi Ishihara; Shigetoshi Kuroda
Journal:  Psychopharmacology (Berl)       Date:  2008-09-06       Impact factor: 4.530

10.  Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone.

Authors:  Deanna L Kelly; Heidi J Wehring; Jared Linthicum; Stephanie Feldman; Robert P McMahon; Raymond C Love; Tara Wagner; Joo Cheol Shim; David R Fowler
Journal:  Schizophr Res       Date:  2008-11-22       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.